These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6831478)

  • 21. The lethal activity and repair inhibition capacity of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466, PCNU), a nitrosourea with low carbamoylating activity.
    Drewinko B; Yang LY
    Invest New Drugs; 1983; 1(3):197-202. PubMed ID: 6678867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 2 evaluation of 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer.
    Ahmann DL; Bisel HF; Hahn RG
    Cancer Res; 1974 Jan; 34(1):27-30. PubMed ID: 4809462
    [No Abstract]   [Full Text] [Related]  

  • 23. PCNU: a new nitrosourea in clinical oncology.
    Poster DS; Penta JS; Bruno S
    Am J Clin Oncol; 1982 Feb; 5(1):9-12. PubMed ID: 7081143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemotherapeutic characterization of new nitrosourea compounds].
    Zeller WJ; Berger MR; Eisenbrand G; Petru E
    Arch Geschwulstforsch; 1988; 58(3):137-49. PubMed ID: 3415433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formulation of three nitrosoureas for intravenous use.
    Davignon JP; Yang KW; Wood HB; Cradock JC
    Cancer Chemother Rep 3; 1973 May; 4(3):7-11. PubMed ID: 4201309
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase I trial of cystemustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme.
    Mathé G; Misset JL; Triana BK; Godenèche D; Madelmont JC; Meyniel G
    Drugs Exp Clin Res; 1992; 18(4):155-8. PubMed ID: 1451646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of a bifunctional derivative of nitrosoalkylurea on the growth of experimetal tumors].
    Vasil'eva LS; Gumanov LL; D'iachkovskaia RF; Konovalova NP; Surkova NI
    Izv Akad Nauk SSSR Biol; 1973; 5():737-9. PubMed ID: 4796871
    [No Abstract]   [Full Text] [Related]  

  • 28. Chemotherapy of breast cancer. Investigational treatment.
    Jones SE
    Ariz Med; 1974 Mar; 31(3):197-8. PubMed ID: 4362033
    [No Abstract]   [Full Text] [Related]  

  • 29. In vivo prediction of drug sensitivity with cancer-seeking isotopes.
    Nathanson L
    Natl Cancer Inst Monogr; 1971 Dec; 34():225-33. PubMed ID: 5140868
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of brain tumors with 1-(2 chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
    Takeuchi J; Nakao S; Handa H
    Nihon Geka Hokan; 1973 Apr; 42(2):184-9. PubMed ID: 4738478
    [No Abstract]   [Full Text] [Related]  

  • 31. Second-line chemotherapy with tauromustine in metastatic breast cancer in postmenopausal women: a phase II study.
    Ernst P; Balslev I; Mouridsen HT
    Cancer Treat Rep; 1987 Oct; 71(10):987-8. PubMed ID: 3652062
    [No Abstract]   [Full Text] [Related]  

  • 32. [Bifunctional derivatives of N-nitroso-alkylurea].
    Emanuel' NM; Konovalova NP; D'iachkovskaia RF; Rozenberg AN
    Vopr Onkol; 1976; 22(10):72-7. PubMed ID: 1014497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracarotid infusion of PCNU (NSC: 95466): preclinical toxicological study in dogs.
    Goumnerova L; Richard MT; Addison D; Montpetit V; Stewart DJ
    J Neurooncol; 1987; 5(3):205-9. PubMed ID: 3681384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contributions of nitrosoureas to cancer treatment.
    Mitchell EP; Schein PS
    Cancer Treat Rep; 1986 Jan; 70(1):31-41. PubMed ID: 3002621
    [No Abstract]   [Full Text] [Related]  

  • 35. [Advances on ACNU in the past 10 years].
    Niitani H
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):727-31. PubMed ID: 3281592
    [No Abstract]   [Full Text] [Related]  

  • 36. [Changes in the proliferative activity of human breast cancer cells cultivated in vivo in diffusion chambers in response to antineoplastic agents].
    Shamaev VI; Krutova TV; D'iachkovskaia RF; Korman DB
    Biull Eksp Biol Med; 1981 Jul; 92(7):77-9. PubMed ID: 6794665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chemotherapeutic combinations of mutually potentializing drugs. 1-Application to the treatment of breast cancers].
    Pouillart P; Schwarzenberg L; Amiel JL; Mathé G; Huguenin P; Morin P; Baron A; Laparre Ch; Parrot R
    Nouv Presse Med; 1975 Mar; 4(10):713-6. PubMed ID: 1129034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma.
    Elson PJ; Earhart RH; Kvols LK; Spiegel R; Keller AM; Kies MS; Davis TE; Stevens C; Gumas L; Trump DL
    Cancer Treat Rep; 1987 Mar; 71(3):331-2. PubMed ID: 3815401
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase II trial with bleomycin, CCNU, and streptozotocin in patients with metastatic cancer of the breast.
    Band PR; Canellos GP; Sears M; Israel L; Pocock SJ
    Cancer Treat Rep; 1977 Oct; 61(7):1365-7. PubMed ID: 73416
    [No Abstract]   [Full Text] [Related]  

  • 40. [Experience with use of mustoforan at the Clinical Oncological Dispensary of the Republic of Tatarstan].
    Karpenko LG
    Vopr Onkol; 2005; 51(3):388-90. PubMed ID: 16279110
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.